## evelyne Crapez

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6348719/publications.pdf

Version: 2024-02-01

1163117 1281871 1,013 11 8 11 citations h-index g-index papers 11 11 11 2205 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nature Medicine, 2014, 20, 430-435.	30.7	582
2	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clinical Cancer Research, 2016, 22, 3067-3077.	7.0	144
3	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Translational Oncology, 2013, 6, 319-IN8.	3.7	143
4	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. British Journal of Cancer, 2018, 119, 76-79.	6.4	48
5	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Clinical Chemistry, 2020, 66, 1093-1101.	3.2	33
6	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancers. Cancers, 2020, 12, 828.	3.7	27
7	The Non-Crosslinking Fixative RCL2 $\hat{A}^{\text{@}}$ -CS100 is Compatible with Both Pathology Diagnosis and Molecular Analyses. Pathology and Oncology Research, 2013, 19, 41-53.	1.9	14
8	Clinicopathological Correlates of $\hat{l}^3\hat{l}^*T$ Cell Infiltration in Triple-Negative Breast Cancer. Cancers, 2021, 13, 765.	3.7	13
9	A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors. Cancers, 2021, 13, 4449.	3.7	5
10	Reproductive Decisionâ€Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. Journal of Genetic Counseling, 2016, 25, 432-442.	1.6	2
11	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of Personalized Medicine, 2022, 12, 655.	2.5	2